Intestinal metaplasia has overexpressions of COX-2.
Short-term 8-week celecoxib, a selective COX-2 inhibitor, exerts a preliminary hint to improve regression in part for persistent intestinal metaplasia after Helicobacter pylori eradication.
Dr Bor-Shyang Sheu and colleagues from Taiwan validated whether or not a prolonged duration of celecoxib of up to 1 year can be safe and effective.
The research team found that 140 patients, with persistent intestinal metaplasia after H. pylori eradication for 1 year, were included with half of them receiving celecoxib 200 mg/day for 12 months and the other half serving as controls.
The team reported that each patient received serial checkups of blood creatinine levels every 4 months.
|One year 200-mg celecoxib daily be safely administered to prevent progression of disease|
After the 1-year follow-up, panendoscopy was repeated to assess the intestinal metaplasia regression.
The serial gastric specimens, taken before and after celecoxib therapy, were immunochemically stained for COX-2.
The intention-to-treat and per-protocol analyses to the rates of intestinal metaplasia regression were higher in the celecoxib group than in the controls.
All enrolled patients had no renal impairment during follow-up.
The team noted that even in the patients without intestinal metaplasia regression, the mean intestinal metaplasia scores and COX-2 expressions were significantly more decreased in the celecoxib group than in the controls.
Dr Sheu's team commented, "One year 200-mg celecoxib daily be safely administered to improve the regression or prevent the progression of persistent intestinal metaplasia after H. pylori eradication."